Ministry of Health (Saudi Arabia)

Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023

Retrieved on: 
星期一, 九月 18, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, European Scientific Cooperative on Phytotherapy, Influenza, Medical Affairs Bureau, MHLW, SARS-CoV-2, Head, Kidney, Ministry of Health, Labour and Welfare, Fast Track, Research, COVID, Ministry, Ensitrelvir, Patient, Risk, Hearing, Ministry of Health (Saudi Arabia), BMI, Regulation of tobacco by the U.S. Food and Drug Administration, Conference, Cancer, Food, Kidney disease, Pharmaceutical industry, Vaccine, Shionogi

Ensitrelvir is an investigational oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.

Key Points: 
  • Ensitrelvir is an investigational oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
  • Known as Xocova® in Japan, ensitrelvir received emergency regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the treatment of SARS-CoV-2 infection in November 2022.
  • In April 2023, ensitrelvir was granted Fast Track designation by the U.S. Food and Drug Administration.
  • “These results indicate the potential for ensitrelvir to help address these needs.”

Malaysian Genomics Unveils Strategic Advances in Biopharmaceuticals

Retrieved on: 
星期二, 八月 29, 2023
Vaccine, Optimism, Genomics, MOH, Danna Azrieli, Ministry, Cosmeceutical, LBT, CGMP, PBT, Ministry of Health (Saudi Arabia), FMCG, Wound healing, Fine chemical, Health

PETALING JAYA, Malaysia, Aug 29, 2023 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, recorded a revenue of RM2.23 million for the 4th quarter ended 30 June 2023.

Key Points: 
  • PETALING JAYA, Malaysia, Aug 29, 2023 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, recorded a revenue of RM2.23 million for the 4th quarter ended 30 June 2023.
  • The Group will continue to implement stringent credit control policy as they move forward with their initiatives, particularly with Rejuvium.
  • For the current year-to-date, MGRC reported a revenue of RM8.36 million, a decrease from RM28.36 million in the previous year.
  • Malaysian Genomics Resource Centre Bhd: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/
    Copyright 2023 ACN Newswire .

Saudi Arabia IVD market rose to $605 Million in 2022, finds global diagnostic market research report

Retrieved on: 
星期五, 七月 21, 2023
Private sector, Research report, Prevalence, Diabetes, COVID-19, 2005 in television, MOH, Ageing, Infection, COVID-19 testing, Ministry, Hospital, Ministry of Health (Saudi Arabia), IVD, Growth, Rest, PCR, Safety, Medical device, Arms industry, Health care, Health insurance, Health

ARLINGTON, Va., July 21, 2023 /PRNewswire-PRWeb/ -- The market for in vitro diagnostics (IVDs) in Saudi Arabia, a young country in an aging world, reached an estimated $605 million in 2022, according to 30-Country IVD Market Atlas, a quarterly updated report from leading diagnostic market research firm Kalorama Information.

Key Points: 
  • Saudi Arabia is one of several major in vitro diagnostic markets analyzed in the research report "30-Country IVD Market Atlas (In Vitro Diagnostic Markets for US, China, Germany, UK, Saudi Arabia, India, UAE, France, Vietnam, Turkey and 20 Other Countries)"
    ARLINGTON, Va., July 21, 2023 /PRNewswire-PRWeb/ -- The market for in vitro diagnostics (IVDs) in Saudi Arabia, a young country in an aging world, reached an estimated $605 million in 2022, according to 30-Country IVD Market Atlas , a quarterly updated report from leading diagnostic market research firm Kalorama Information.
  • Saudi Arabia's IVD market is forecast to have a CAGR of 3.8% between 2021 and 2026.
  • In Saudi Arabia, the IVD market is largely made up of imports as domestic manufacturing of diagnostic tests is nearly nonexistent, according to Kalorama.
  • Although Saudi Arabia is home to more than 35 million people, only 3% are 65 years or older.

Ginkgo Bioworks and the Ministry of Health of the Republic of Botswana Announce Pathogen Monitoring Program at Key Ports of Entry

Retrieved on: 
星期一, 七月 17, 2023
DNA, Biosecurity, GBE, SARS-CoV-2, Public, MOH, Biotechnology, Concentric objects, Livestock, Global health, Government, Ministry, International airport, Republic, Ginkgo Bioworks, Ginkgo, MOU, Ministry of Health (Saudi Arabia), NYSE, Vaccine

BOSTON and GABORONE, Botswana, July 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Ministry of Health ("MoH") representing the Government of the Republic of Botswana today announced a pathogen monitoring program at key ports of entry to identify new and emerging variants of SARS-CoV-2.

Key Points: 
  • BOSTON and GABORONE, Botswana, July 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Ministry of Health ("MoH") representing the Government of the Republic of Botswana today announced a pathogen monitoring program at key ports of entry to identify new and emerging variants of SARS-CoV-2.
  • The program builds on Ginkgo's previously announced MOU to develop and implement biosecurity capabilities in Botswana, and will also incorporate pathogen monitoring at land borders, at municipal wastewater treatment works, and for livestock in the food system.
  • This program is built upon a shared recognition by Concentric and the Botswana MoH of the importance of international collaboration and cooperation to promote global health security.
  • Effective pathogen monitoring and data sharing capabilities can empower government officials, community leaders, and other stakeholders to make informed public health decisions.

UZBEKISTAN CONFERENCE GUESTS TOUT EMERGING 'EURASIAN TIGER' ECONOMY

Retrieved on: 
星期五, 七月 7, 2023
Sustainability, Interfaith Center for Sustainable Development, English, Partnership, Education, DL, Suggestion, CIS, Research, Transport, UNICEF, Thought, Pacific Ocean, Organization, Ministry, Popularity, Republic, Ministry of Health (Saudi Arabia), Artificial intelligence, Climate, House music, Constitution, Live in the UK (House of Lords album), Tourism, Pharmaceutical industry, Science, Health

TASHKENT, Uzbekistan, July 7, 2023 /PRNewswire/ -- Day 4 of a week-long international conference entitled 'New Uzbekistan: development, innovation and enlightenment' turned its focus to the country's regional leadership role, with the concept of Uzbekistan as a 'Eurasian Tiger' taking shape.

Key Points: 
  • TASHKENT, Uzbekistan, July 7, 2023 /PRNewswire/ -- Day 4 of a week-long international conference entitled 'New Uzbekistan: development, innovation and enlightenment' turned its focus to the country's regional leadership role, with the concept of Uzbekistan as a 'Eurasian Tiger' taking shape.
  • That's why we selected to participate in Uzbekistan among all the CIS countries.
  • The importance of Uzbekistan in an east-west land corridor, the so-called 'New Silk Road' was raised by Wang Gochao of Lianyungang Port Group in China.
  • "I'm very very proud to say that Uzbekistan has implemented a national program to fund and support Hepatitis C elimination by 2030.

UZBEKISTAN CONFERENCE GUESTS TOUT EMERGING 'EURASIAN TIGER' ECONOMY

Retrieved on: 
星期五, 七月 7, 2023
Sustainability, Interfaith Center for Sustainable Development, English, Partnership, Education, DL, Suggestion, CIS, Research, Transport, UNICEF, Thought, Pacific Ocean, Organization, Ministry, Popularity, Republic, Ministry of Health (Saudi Arabia), Artificial intelligence, Climate, House music, Constitution, Live in the UK (House of Lords album), Tourism, Pharmaceutical industry, Science, Health

TASHKENT, Uzbekistan, July 7, 2023 /PRNewswire/ -- Day 4 of a week-long international conference entitled 'New Uzbekistan: development, innovation and enlightenment' turned its focus to the country's regional leadership role, with the concept of Uzbekistan as a 'Eurasian Tiger' taking shape.

Key Points: 
  • TASHKENT, Uzbekistan, July 7, 2023 /PRNewswire/ -- Day 4 of a week-long international conference entitled 'New Uzbekistan: development, innovation and enlightenment' turned its focus to the country's regional leadership role, with the concept of Uzbekistan as a 'Eurasian Tiger' taking shape.
  • That's why we selected to participate in Uzbekistan among all the CIS countries.
  • The importance of Uzbekistan in an east-west land corridor, the so-called 'New Silk Road' was raised by Wang Gochao of Lianyungang Port Group in China.
  • "I'm very very proud to say that Uzbekistan has implemented a national program to fund and support Hepatitis C elimination by 2030.

Emergex and Brazil’s IBMP Announce Clinical Development Collaboration for T Cell-Priming Immune Set-Point Candidates

Retrieved on: 
星期二, 六月 20, 2023
Vaccine, Fever, Yellow fever, Dengue fever, ANVISA, UKM Medical Molecular Biology Institute, Clinical trial, Research, Ministry, Molecular biology, Death, Ministry of Health (Saudi Arabia), Universal, IBMP, Pharmaceutical industry, Betacoronavirus, Health, Coronavirus, Brazilian, Chikungunya

Fiocruz has a strong commercial track record in the healthcare space, with expertise in the development, manufacturing, regulatory approval, and commercialization of medicines and medical diagnostics in Brazil.

Key Points: 
  • Fiocruz has a strong commercial track record in the healthcare space, with expertise in the development, manufacturing, regulatory approval, and commercialization of medicines and medical diagnostics in Brazil.
  • Both clinical trial product candidates have successfully completed Phase I+ clinical trials in Switzerland and are nearing submission and evaluation by ANVISA, the Brazilian health regulatory agency.
  • A Joint Steering Committee with representatives from both Emergex and IBMP will oversee the collaboration and commercialization of the select immunotherapies.
  • IBMP has also made an early equity investment into Emergex, which has potential for future expansion pending the completion of its ongoing due diligence process.

Digital Therapeutics Alliance and Healthware Group Launched First DTx Policy Report and Website Dedicated to Helping Advance Equitable Access and Adoption of Safe and Effective DTx and Digital Medical Devices

Retrieved on: 
星期一, 六月 12, 2023
Other Health, General Health, Professional Services, Pharmaceutical, Telemedicine, Virtual Medicine, Biometrics, Medical Devices, Health Technology, Data Analytics, Biotechnology, Consulting, Health, Single-frequency network, AID, Monetary Policy Report to the Congress, DTA, Therapy, Education, Marketing, Coalition, Policy, Innovation, HTA, Multimedia, Ministry of Health (Saudi Arabia), DMD, Digital health, Patient, European Network for Health Technology Assessment, Knowledge, Growth, Ecosystem, Digital, Healthware International, Health technology assessment, Caregiver, Video game, Medical device, Database, European

Their collective efforts aim to establish comprehensive best practice frameworks for the utilization of digital medical devices (DMD), including digital therapeutics (DTx).

Key Points: 
  • Their collective efforts aim to establish comprehensive best practice frameworks for the utilization of digital medical devices (DMD), including digital therapeutics (DTx).
  • To address this challenge, this initial DTx Policy Report is focused on providing clarity on existing and evolving policy frameworks in Europe.
  • Founded in 2017, the Digital Therapeutics Alliance is a 501(c)(6) non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics.
  • DTA is mission driven to advance digital therapeutics globally by:
    To learn more, please visit: www.dtxalliance.org or follow us on LinkedIn.

Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
星期一, 五月 8, 2023
NCT, Netherton syndrome, Cohort, European Medicines Agency, Ministry of Health, Labour and Welfare, Cystic fibrosis, Phase 1, Investment, Patient, Cystic Fibrosis Foundation, TGM1, Ministry of Health (Saudi Arabia), Association for Research in Vision and Ophthalmology, ARVO, Prescription Drug User Fee Act, Pannus, AATD, Rare, Jeune, FDA, IND, Skin, Safety, PIP, RDEB, Eye, Ministry, Financial result, Form, Research, Therapy, KRYS, DEB, MHLW, Clinical trial, Marketing, Annual general meeting, Pharmaceutical industry, Maple syrup, Ophthalmology, PDUFA, Health

Financial results for the quarter ended March 31, 2023:

Key Points: 
  • Financial results for the quarter ended March 31, 2023:
    Cash, cash equivalents, and investments totaled $355.5 million on March 31, 2023.
  • Research and development expenses for the quarter ended March 31, 2023 were $12.3 million, compared to $9.3 million for the quarter ended March 31, 2022.
  • General and administrative expenses for the quarter ended March 31, 2023 were $24.0 million, compared to $15.9 million for the quarter ended March 31, 2022.
  • For additional information on the Company’s financial results for the quarter ended March 31, 2023, please refer to the Form 10-Q filed with the SEC.

ECCMID 2023: Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment

Retrieved on: 
星期二, 四月 4, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, COVID-19, Infectious Diseases, Clinical Trials, MHLW, SARS-CoV-2, Head, Ministry of Health, Labour and Welfare, Fast Track, Infection, RNA, Ministry, Ensitrelvir, Congress, ECCMID, Patient, European, Ministry of Health (Saudi Arabia), FDA, Recurrence, Generic, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PCR, Food, Pharmaceutical industry, Vaccine, Shionogi

: S-217622, hereafter “ensitrelvir”) will be published as posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark 15 - 18 April 2023.

Key Points: 
  • : S-217622, hereafter “ensitrelvir”) will be published as posters at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Copenhagen, Denmark 15 - 18 April 2023.
  • Ensitrelvir, known as Xocova® 125 mg tablet in Japan, received emergency regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the treatment of SARS-CoV-2 infection.
  • The first late-breaking poster presentation included a post-hoc analysis of the Phase 3 part showing that viral rebound and symptom recurrence were infrequently seen up to 21 days after treatment with ensitrelvir.
  • Symptom recurrence was rare and was not associated with viral RNA rebound.